内科理论与实践 ›› 2022, Vol. 17 ›› Issue (04): 307-312.doi: 10.16138/j.1673-6087.2022.04.007
收稿日期:
2022-01-27
出版日期:
2022-07-18
发布日期:
2022-08-08
通讯作者:
璩斌
E-mail:qb3793@163.com
ZHANG Xiaoyana, XU Jingb, QU Binc()
Received:
2022-01-27
Online:
2022-07-18
Published:
2022-08-08
Contact:
QU Bin
E-mail:qb3793@163.com
摘要:
目的: 探讨血清维生素D水平对老年慢性肾脏病(chronic kidney disease, CKD)患者肾功能的影响。方法: 收集2014年1月至2019年5月在上海交通大学医学院附属瑞金医院肾脏科和老年科诊治的年龄≥60岁CKD 1~4期患者的临床及随访资料。采用化学发光法测定血清25羟维生素D[25(OH) D ]水平,按25(OH)D水平将患者分为维生素D缺乏组 [25(OH)D<50 nmol/L] 及不缺乏组 [包括充足及不足,即25(OH)D≥50 nmol/L]。比较2组患者基线临床及预后指标。结果: 共纳入347例老年CKD患者,与CKD1~2期患者相比,CKD 3期及以上患者的维生素D水平显著降低。维生素D缺乏发生率在CKD 1~2期和CKD 3期及以上患者的发生率分别为46.7%、67.6%。在CKD 3期及以上患者中,与维生素D不缺乏组相比,维生素D缺乏组患者甲状旁腺素、血尿酸及血肌酐水平较高,而血钙及估算的肾小球滤过率(estimated glomerular filtration rate,eGFR)较低,且维生素D缺乏组较不缺乏组发生eGFR下降≥30%或出现终末期肾脏病的比例较高(16.9%比2.9%,P=0.042)。多因素Logistic回归分析显示,维生素D缺乏独立于男性、年龄大、高平均动脉压、低血红蛋白、低白蛋白、高蛋白尿及高尿酸,为发生3期及以上CKD的独立风险因素。结论: 在老年CKD 3~4期患者中,维生素D缺乏组患者的eGFR显著下降,且维生素D缺乏是发生3期及以上CKD进展的独立危险因素。
中图分类号:
章晓炎, 徐静, 璩斌. 血清维生素D水平对老年慢性肾脏病患者肾功能的影响[J]. 内科理论与实践, 2022, 17(04): 307-312.
ZHANG Xiaoyan, XU Jing, QU Bin. Effect of serum vitamin D level on renal function in elderly patients with chronic kidney disease[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 307-312.
表1
不同CKD分期临床指标的比较[n(%)/($\bar{x}\pm s$)中位数(全距)]
项目 | CKD 1~2期(n=242) | CKD 3期及以上(n=105) | P |
---|---|---|---|
男/女(n) | 116/126 | 58/47 | 0.211 |
年龄(岁) | 76.0(70.0~83.0) | 78.0(71.0~84.0) | 0.265 |
收缩压(mmHg) | 134.0(120.0~148.0) | 133.0(120.0~149.0) | 0.737 |
舒张压(mmHg) | 70.0(65.0~80.0) | 70.0(64.5~80.0) | 0.707 |
白细胞(×109/L) | 6.0(5.0~7.1) | 6.8(5.0~8.2) | 0.026 |
血红蛋白(g/L) | 130.7±18.2 | 119.1±17.5 | 0.639 |
白蛋白(g/L) | 37.0(34.0~40.0) | 35.0(32.0~38.5) | <0.001 |
25(OH)D(nmol/L) | 52.6(37.4~70.8) | 42.5(34.5~53.6) | <0.001 |
血钙(mmol/L) | 2.2±0.1 | 2.2±0.2 | 0.123 |
血磷(mmol/L) | 1.0±0.2 | 1.0±0.1 | 0.295 |
甲状旁腺素(ng/L) | 50.5(38.7~61.5) | 52.9(35.6~69.1) | 0.813 |
尿蛋白量(g/24 h) | 0.3(0.2~0.8) | 0.9(0.4~1.9) | <0.001 |
血尿酸(μmol/L) | 307.5.0(262.8~365.3) | 380.0(331.5~457.5) | <0.001 |
血肌酐(μmol/L) | 73.5(65.0~81.0) | 113.0(101.5~140.0) | <0.001 |
eGFR[mL/(min·1.73 m2)] | 79.2(68.9~87.3) | 45.7(35.2~53.2) | <0.001 |
甘油三酯(mmol/L) | 1.5±0.9 | 1.7±1.0 | 0.106 |
胆固醇(mmol/L) | 4.6±1.4 | 5.0±1.4 | 0.165 |
糖化血红蛋白(%) | 5.9(5.6~6.4) | 6.4(5.8~7.3) | 0.786 |
发生终点事件[n(%)] | 17(7.0) | 13(12.4) | 0.103 |
表2
不同eGFR水平时维生素D缺乏组与不缺乏组临床指标的比较[n(%)/$\bar{x}\pm s$)]
项目 | CKD 1~2期(n=242) | CKD 3期及以上(n=105) | |||||
---|---|---|---|---|---|---|---|
维生素D缺乏组 (n=113) | 维生素D不缺乏组 (n=129) | P | 维生素D缺乏组 (n=71) | 维生素D不缺乏组 (n=34) | P | ||
男/女(n) | 58/71 | 58/55 | 0.323 | 40/31 | 18/16 | 0.743 | |
年龄(岁) | 77.0(72.0~84.0) | 75.0(68.0~82.5) | 0.119 | 76.0(70.0~84.0) | 80.0(73.0~85.0) | 0.361 | |
收缩压(mmHg) | 138.0(123.0~151.5) | 130.0(119.0~143.0) | 0.030 | 134.0(120.0~149.0) | 131.5(120.0~149.3) | 0.997 | |
舒张压(mmHg) | 72.0(65.5~80.0) | 70.0(65.0~79.5) | 0.350 | 70.0(64.0~80.0) | 72.0(64.8~80.0) | 0.771 | |
白细胞(×109/L) | 5.8(4.7~7.0) | 6.2(5.4~7.5) | 0.020 | 6.6(5.0~8.2) | 7.0(5.2~8.6) | 0.488 | |
血红蛋白(g/L) | 133.6±19.4 | 128.2±16.7 | 0.021 | 118.6±17.2 | 120.2±18.3 | 0.672 | |
白蛋白(g/L) | 38.0(35.0~42.0) | 37.0(33.0~40.0) | 0.013 | 35.0(32.0~37.0) | 34.5(32.8~40) | 0.527 | |
血钙(mmol/L) | 2.19±0.12 | 2.23±0.12 | 0.009 | 2.16±0.12 | 2.29±0.23 | 0.030 | |
血磷(mmol/L) | 1.04±0.16 | 1.08±0.17 | 0.162 | 1.02±0.09 | 1.05±0.18 | 0.383 | |
甲状旁腺素(ng/L) | 55.5(42.0~67.2) | 44.2(35.7~58.7) | 0.014 | 62.2(52.8~74.0) | 38.9(30.2~51.9) | 0.002 | |
尿蛋白量(g/24 h) | 0.30(0.19~0.78) | 0.35(0.20~0.84) | 0.745 | 0.90(0.39~2.07) | 0.86(0.40~1.57) | 0.937 | |
血尿酸(μmol/L) | 306.0(265.0~358.0) | 310.0(257.0~368.0) | 0.961 | 390.0(336.0~473.0) | 370.0(323.5~385.5) | 0.026 | |
血肌酐(μmol/L) | 74.0(65.0~83.0) | 73.0(65.5~80.0) | 0.244 | 115.0(104.0~152.0) | 106.0(87.5~116.3) | 0.001 | |
eGFR[mL/(min·1.73 m2)] | 79.2(72.3~83.4) | 76.3(66.9~86.8) | 0.170 | 42.1(30.1~50.3) | 50.8(44.5~55.2) | <0.001 | |
甘油三酯(mmol/L) | 1.4±0.7 | 1.5±1.1 | 0.150 | 1.8±1.2 | 1.5±0.9 | 0.177 | |
总胆固醇(mmol/L) | 4.4±1.3 | 4.7±1.4 | 0.178 | 5.0±1.2 | 4.8±1.7 | 0.439 | |
糖化血红蛋白(%) | 5.9(5.6~6.4) | 5.9(5.6~6.2) | 0.390 | 5.9(5.4~6.2) | 5.9(5.7~6.5) | 0.148 | |
发生终点事件[n(%)] | 8(7.1) | 9(7.0) | 0.975 | 12(16.9) | 1(2.9) | 0.042 |
表3
单因素和多因素Logistic分析患者发生3期及以上CKD的影响因素
变量 | 单因素 | 多因素 | |||
---|---|---|---|---|---|
OR(95%CI) | P | OR(95%CI) | P | ||
男性 | 1.340(0.846~2.124) | 0.212 | 1.458(0.745~2.855) | 0.271 | |
年龄 | 1.016(0.990~1.044) | 0.230 | 1.033(0.994~1.073) | 0.097 | |
平均动脉压 | 1.005(0.987~1.023) | 0.609 | 1.023(0.996~1.050) | 0.096 | |
血红蛋白 | 0.965(0.952~0.978) | <0.001 | 0.958(0.939~0.977) | <0.001 | |
白蛋白 | 0.942(0.906~0.980) | 0.003 | 0.991(0.931~1.054) | 0.775 | |
尿蛋白量 | 1.857(1.435~2.405) | <0.001 | 1.667(1.185~2.345) | 0.003 | |
尿酸 | 1.012(1.009~1.016) | <0.001 | 1.013(1.008~1.018) | <0.001 | |
维生素D缺乏 | 2.384(1.474~3.854) | <0.001 | 2.559(1.326~4.937) | 0.005 |
[1] |
Michener KH, Mitchell GF, Noubary F, et al. Aortic stiffness and kidney disease in an elderly population[J]. Am J Nephrol, 2015, 41(4-5): 320-328.
doi: 10.1159/000431332 URL |
[2] |
Hruska KA, Sugatani T, Agapova O, et al. The chronic kidney disease - mineral bone disorder (CKD-MBD): advances in pathophysiology[J]. Bone, 2017, 100: 80-86.
doi: S8756-3282(17)30023-6 pmid: 28119179 |
[3] | ANON. Kidney disease: improving global outcomes CKDMBDUWG, KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD)[J]. Kidney Int Suppl(2011), 2017, 7(1):1-59. |
[4] | Boucher BJ. The problems of vitamin d insufficiency in older people[J]. Aging Dis, 2012, 3(4): 313-329. |
[5] |
Berridge MJ. Vitamin D deficiency and diabetes[J]. Biochem J, 2017, 474(8): 1321-1332.
doi: 10.1042/BCJ20170042 pmid: 28341729 |
[6] | Jeong HY, Park KM, Lee MJ, et al. Vitamin D and hypertension[J]. Electrolyte Blood Press, 2017. 15(1): 1-11. |
[7] |
Kiss I, Kiss Z, Ambrus C, et al. Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in hungary—results from a nationwide clinical audit[J]. BMC Nephrol, 2013, 14: 155.
doi: 10.1186/1471-2369-14-155 URL |
[8] |
Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines—application to the individual patient[J]. Kidney Int, 2012, 82(8): 840-856.
doi: 10.1038/ki.2012.280 pmid: 22895519 |
[9] |
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med, 2009, 150(9): 604-612.
doi: 10.7326/0003-4819-150-9-200905050-00006 URL |
[10] | 中国医师协会肾脏内科医师分会维生素D实践方案专家协作组. 维生素D及其类似物在慢性肾脏病患者中应用的中国实践方案(2019版)[J]. 中华内科杂志, 2020, 59(2): 104-116. |
[11] | Franca Gois PH, Wolley M, Ranganathan D, et al. Vitamin D deficiency in chronic kidney disease: recent evidence and controversies[J]. Int J Environ Res Public Health, 2018, 15(8): 1773. |
[12] |
Morrone LF, Bolasco P, Camerini C, et al. Vitamin D in patients with chronic kidney disease: a position statement of the Working Group“Trace Elements and Mineral Metabolism” of the Italian Society of Nephrology[J]. J Nephrol, 2016, 29(3): 305-328.
doi: 10.1007/s40620-016-0305-6 URL |
[13] |
LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States[J]. Am J Kidney Dis, 2005, 45(6): 1026-1033.
doi: 10.1053/j.ajkd.2005.02.029 pmid: 15957131 |
[14] |
Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease[J]. Kidney Int, 2009, 75(1): 88-95.
doi: 10.1038/ki.2008.501 URL |
[15] |
Satirapoj B, Limwannata P, Chaiprasert A, et al. Vitamin D insufficiency and deficiency with stages of chronic kidney disease in an Asian population[J]. BMC Nephrol, 2013, 14: 206.
doi: 10.1186/1471-2369-14-206 pmid: 24083392 |
[16] |
Tapper M, McGrowder DA, Dilworth L, et al. Cystatin C, vitamin D and thyroid function test profile in chronic kidney disease patients[J]. Diseases, 2021, 9(1): 5.
doi: 10.3390/diseases9010005 URL |
[17] | Ghosh SK, Ghosh S. Cross-sectional study on vitamin D status in CKD patients[J]. J Assoc Physicians India, 2020, 68(4): 26-28. |
[18] | 吕轶伦, 林颍, 史浩, 等. 慢性肾脏病患者维生素D不足与缺乏[J]. 中华肾脏病杂志, 2009, 25(9): 668-672. |
[19] |
Sah SK, Adhikary LP. Prevalence of abnormal serum 25-hydroxyvitamin D and its association with hemoglobin level in pre dialysis CKD patients: a cross-sectional study from Himalayan country[J]. BMC Nephrol, 2019, 20(1): 267.
doi: 10.1186/s12882-019-1443-6 URL |
[20] |
Wang Y, Zheng Y, Chen P, et al. The weak correlation between serum vitamin levels and chronic kidney disease in hospitalized patients[J]. BMC Nephrol, 2021, 22(1): 292.
doi: 10.1186/s12882-021-02498-5 URL |
[21] |
Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease[J]. Clin J Am Soc Nephrol, 2009, 4(6): 1128-1135.
doi: 10.2215/CJN.00260109 URL |
[22] |
Pilz S, Tomaschitz A, Friedl C, et al. Vitamin D status and mortality in chronic kidney disease[J]. Nephrol Dial Transplant, 2011, 26(11): 3603-3609.
doi: 10.1093/ndt/gfr076 URL |
[23] |
Guessous I, McClellan W, Kleinbaum D, et al. Serum 25-hydroxyvitamin D level and kidney function decline in a Swiss general adult population[J]. Clin J Am Soc Nephrol, 2015, 10(7): 1162-1169.
doi: 10.2215/CJN.04960514 URL |
[24] |
Xu J, Yang J, Chen J, et al. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system[J]. Mol Med Rep, 2017, 16(5): 7432-7438.
doi: 10.3892/mmr.2017.7546 URL |
[25] |
Eltablawy N, Ashour H, Rashed LA, et al. Vitamin D protection from rat diabetic nephropathy is partly mediated through Klotho expression and renin-angiotensin inhibition[J]. Arch Physiol Biochem, 2018, 124(5): 461-467.
doi: 10.1080/13813455.2018.1423624 pmid: 29308676 |
[26] | Zhang CJ, Zhao D, Yin X, et al. Effects of 1,25(OH)2D3 on proliferation and apoptosis of human glomerular mesangial cells[J]. Am J Transl Res, 2016, 8(6): 2659-2666. |
[27] | Santoro D, Caccamo D, Lucisano S, et al. Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system[J]. Biomed Res Int, 2015, 2015: 145828. |
[28] |
Lucisano S, Buemi M, Passantino A, et al. New insights on the role of vitamin D in the progression of renal damage[J]. Kidney Blood Press Res, 2013, 37(6): 667-678.
doi: 10.1159/000355747 URL |
[29] | Zhang YY, Qiu HB, Tian JW. Association between vitamin D and hyperuricemia among adults in the United States[J]. Front Nutr, 2020, 7: 592777. |
[30] |
Faridi KF, Lupton JR, Martin SS, et al. Vitamin D deficiency and non-lipid biomarkers of cardiovascular risk[J]. Arch Med Sci, 2017, 13(4): 732-737.
doi: 10.5114/aoms.2017.68237 pmid: 28721139 |
[31] | Peng H, Li H, Li C, et al. Association between vitamin D insufficiency and elevated serum uric acid among middle-aged and elderly Chinese Han women[J]. PLoS One, 2013, 8(4): e61159. |
[1] | 崔晓红, 李嫣然, 李菲卡, 吴方, 胡家安, 陶婷,. 老年人血浆高半胱氨酸水平与肾功能的相关性研究[J]. 内科理论与实践, 2018, 13(04): 223-226. |
[2] | 张凌, 熊敏,. 肾移植与三发性甲状旁腺功能亢进[J]. 内科理论与实践, 2018, 13(04): 197-201. |
[3] | 李涛. 肝癌治疗应重视——肿瘤溶解综合征[J]. 外科理论与实践, 2018, 23(03): 214-216. |
[4] | 程群,. 维生素D缺乏现状与骨质疏松症关系的认识[J]. 诊断学理论与实践, 2012, 11(01): 5-10. |
[5] | 曹立秀, 张欢, 肖华, 杨文洁, 庞丽芳, 卜玉莲, 潘自来, 陈克敏, 严福华,. 中-重度肾功能不全患者冠状动脉病变的CT诊断研究[J]. 诊断学理论与实践, 2011, 10(06): 523-526. |
[6] | 史浩, 张文, 李晓, 沈平雁, 胡炯, 陈楠,. 骨髓瘤肾病患者自体外周血干细胞移植治疗临床分析[J]. 内科理论与实践, 2011, 6(05): 356-360. |
[7] | 邢小平, 王鸥, 孟迅吾, 夏维波, 李梅, 姜艳, 韩桂艳, 胡莹莹, 刘怀成,. 北京与纽约原发性甲状旁腺功能亢进症临床表现的比较[J]. 诊断学理论与实践, 2006, 5(06): 483-486. |
[8] | 战玉喜, 李建新, 张峰, 王均梅, 郑楠,. 血清半胱氨酸蛋白酶抑制剂C对肾小球滤过功能受损的临床意义[J]. 诊断学理论与实践, 2006, 5(05): 437-438. |
[9] | 陈纪言, 杨峻青,. 冠心病,传统危险因素之外的危险状态[J]. 内科理论与实践, 2006, 1(02): 91-93. |
[10] | 陈楠. 肾小球滤过功能检测方法的评估[J]. 诊断学理论与实践, 2003, 2(04): 9-11. |
[11] | 沈卫峰,倪钧. 重视冠心病病人肾动脉狭窄的早期检出[J]. 诊断学理论与实践, 2002, 1(04): 8-10. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||